contact us

PLEASE DO NOT LEAVE ANY CONFIDENTIAL TREATMENT DATA, PRIVATE PATIENT DETAILS OR ANY OTHER PROTECTED HEALTH INFORMATION (PHI) ON THIS SITE. THIS IS IN ORDER TO ENSURE PRIVACY AND REGULATORY COMPLIANCE WITH APPLICABLE PRIVACY RULES AND LAWS (INCLUDING BUT NOT LIMITED TO HIPAA).

About BrainsWay

BrainsWay has revolutionized brain disorder treatments.
BrainsWay’s therapy can help patients regain well-being, calm and happiness in just a few weeks.

BrainsWay is dedicated to developing and providing advanced brain disorder solutions. The company was established in 2003, and became a public company traded on the Tel-Aviv Stock Exchange in January 2007. BrainsWay’s flagship technology, which is based on Deep Transcranial Magnetic Stimulation (TMS), launches a new era in brain disorder treatment.

BrainsWay’s treatment is based on patents filed by the U.S. National Institutes of Health (NIH), and by the company. The company holds an exclusive license from the NIH for the patent and for its unique technology.

BrainsWay’s treatment is FDA cleared for treating depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode (FDA 510(k) No. K122288).

BrainsWay runs clinical research programs with leading scientists worldwide, collaborating with prominent institutions and researchers in clinical trials covering various neuropsychiatric and neuroscience applications.

The company’s technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials held across the globe.

* BrainsWay and the BrainsWay logo are trademarks of BrainsWay Ltd.

Investors Relations

At least 7 characters please!


BrainsWay is dedicated to developing and providing advanced technology solutions for the treatment of a variety of brain disorders. The company was established in 2003, and became a public company traded on the Tel-Aviv Stock Exchange in January 2007. BrainsWay’s flagship technology is based on Deep Transcranial Magnetic Stimulation, which launches a new era in brain disorder treatment.

BrainsWay’s technology is based on patents filed by the U.S. National Institutes of Health (NIH), and by the company. The company holds an exclusive license from the NIH for the patent and for it’s unique technology.

BrainsWay D is FDA cleared for treating depressive episodes in adult patients suffering from Major Depressive Disorder (MDD), who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode (FDA 510(k) No. K122288).

The company’s technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials held across the globe.

PLEASE DO NOT LEAVE ANY CONFIDENTIAL TREATMENT DATA, PRIVATE PATIENT DETAILS OR ANY OTHER PROTECTED HEALTH INFORMATION (PHI) ON THIS SITE. THIS IS IN ORDER TO ENSURE PRIVACY AND REGULATORY COMPLIANCE WITH APPLICABLE PRIVACY RULES AND LAWS (INCLUDING BUT NOT LIMITED TO HIPAA).

financial reports